At a glance
ClinicalIndex Comparison RecordN/ACompleted· 41 enrolled
Drug / intervention
Lisinoprildrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Renin-Angiotensin-Aldosterone System and Parathyroid Hormone Control: The RAAS-PARC Study
In Brief
A clinical study evaluating Lisinopril for Hyperparathyroidism. Completed, enrolled 41 participants across 1 site.
Detailed Summary
This study will evaluate whether commonly used blood pressure medications called "ACE inhibitors" can lower parathyroid hormone.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHyperparathyroidism
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedSep 2012
Enrollment StartOct 2012
Primary CompletionAug 2016
Study CompletionDec 2016
TodayJul 2026
First PostedSep 25, 2012
Enrollment StartOct 1, 2012
Primary CompletionAug 1, 2016
Study CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 13.8 years ago
Interventions
Lisinoprildrug
Each subject will receive one week of lisinopril and return for repeat for blood measurements.